FSD Pharma Inc. Announces Closing of Private Placement
FSD Pharma Inc. Announces Closing of Private Placement
TORONTO, ON / ACCESSWIRE / December 5, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (the "Company" or "FSD"), is pleased to announce that, further to its news release on November 27, 2023, it has closed a non-brokered private placement and issued 24 class A multiple voting shares ("Class A Shares") of the Company at a price of $1.90 per Class A Share for gross proceeds of $45.60 (the "Offering").
安大略省多倫多/ACCESSWIRE/2023年12月5日/富世達製藥公司(納斯達克股票代碼:HUGE)(CSE:HUGE)(FRA: 0K9A)(“公司” 或 “FSD”)欣然宣佈,繼2023年11月27日發佈新聞稿後,該公司已完成非經紀私募併發行了24股A類多表決權股票(“A類股票”)每股A類股票的價格爲1.90美元,總收益爲45.60美元(“發行”)。
All securities issued pursuant to the Offering are subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws of Canada. The Company intends to use the proceeds of the Offering for general working capital purposes.
根據加拿大適用的證券法,根據本次發行發行的所有證券的法定持有期爲四個月外加發行之日起一天。公司打算將本次發行的收益用於一般營運資金用途。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
本新聞稿不應構成出售要約或招攬買入要約,也不得在任何將此類要約、招標或出售爲非法的州出售證券。所發行的證券過去和將來都沒有根據經修訂的1933年《美國證券法》進行註冊,如果沒有註冊或不受經修訂的1933年《美國證券法》和適用的州證券法的註冊要求的適用豁免,則不得在美國發行或出售。
MI 61-101 Disclosure
密歇根州 61-101 披露
Xorax Family Trust ("Xorax"), a trust of which Zeeshan Saeed, the Chief Executive Officer and Co-Chairman of FSD Pharma is a beneficiary, and Fortius Research and Trading Corp. ("Fortius"), a corporation of which Anthony Durkacz, a director of FSD is a director, purchased all the Class A Shares issued pursuant to the Offering. The participation by such insiders is considered a "related-party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61- 101).
Xorax Family Trust(“Xorax”)(FSD Pharma首席執行官兼聯席董事長Zeeshan Saeed是該信託的受益人)和Fortius Research and Trading Corp.(“Fortius”)(Fsd董事安東尼·杜爾卡奇擔任其董事的公司)購買了根據本次發行的所有A類股票。此類內部人士的參與被視爲《多邊文書》61-101所指的 “關聯方交易” -在特殊交易中保護少數證券持有人 (“MI 61-101”)。對於關聯方參與本次發行,公司依據分別載於MI 61-101的第5.5 (a) 和5.7 (1) (a) 節中MI 61-101的正式估值和小股東批准要求的豁免,既不是交易標的的的的公允市場價值(根據MI 61-101確定),也不是交易對價的公允市場價值,因爲該交易涉及關聯方,超過公司市值的25%(根據MI 61-101確定)。
The Company did not file a material change report more than 21 days before the expected closing of the Offering because the details of the participation therein by related parties to the Company were not settled until shortly prior to the closing, and the Company wished to close on an expedited basis for business reasons.
由於公司關聯方參與本次發行的細節直到收盤前不久才確定,而且出於業務原因,公司希望加快完成本次發行的重大變更報告,因此該公司希望加快完成本次發行。
Early Warning Disclosure
預警披露
This press release is being issued in accordance with the requirements of National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with the filing of the Early Warning Reports by Xorax, whose registered address is 3688 Stratton Woods Court, Mississauga, Ontario, L5L 4V2, and Fortius, whose registered address is 2045 Lakeshore Boulevard West, Suite 3006, Toronto, Ontario M6V 2Z6 (collectively, the "Acquirors") in respect of the Offering of the Company, whose registered address is 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
本新聞稿是根據國家儀器62-103的要求發佈的- 預警系統及相關的收購投標和內幕舉報問題 (“NI 62-103”),涉及Xorax(註冊地址爲安大略省密西沙加斯特拉頓伍茲法院3688號,L5L 4V2)和註冊地址爲安大略省多倫多湖岸大道西2045號3006套房 M6V 2Z6(統稱 “收購方”)提交的預警報告該公司的註冊地址爲加拿大安大略省多倫多灣街199號4000套房 M5L 1A9。
On December 4, 2023, Xorax acquired 12 Class A Shares at a price of $1.90 per share for a total price of $22.80 and Fortius acquired 12 Class A Shares at a price of $1.90 per share for a total price of $22.80 pursuant to the Offering
2023年12月4日,Xorax根據本次發行,以每股1.90美元的價格收購了12股A類股票,總價爲22.80美元,Fortius以每股1.90美元的價格收購了12股A類股票,總價爲22.80美元
Following the Offering, Xorax owns 36 Class A Shares and 441,031 class B subordinate voting shares ("Class B Shares") representing 50% of the outstanding Class A Shares, 1.12% of the outstanding Class B Shares, and 17.54% of the voting rights attached to all of the Company's outstanding voting securities. Prior to the Offering, Xorax owned 24 Class A Shares and 441,031 Class B Shares, which represented 50% of the outstanding Class A Shares, 1.12% of the outstanding Class B Shares, and 13.45% of the voting rights attached to all of the Company's outstanding voting securities.
發行後,Xorax擁有36股A類股票和441,031股B類次級有表決權股票(“B類股票”),佔已發行A類股票的50%,佔已發行B類股票的1.12%,以及公司所有已發行有表決權證券的17.54%。在發行之前,Xorax擁有24股A類股票和441,031股B類股票,佔已發行A類股票的50%,佔已發行B類股票的1.12%,以及公司所有已發行有表決權證券的13.45%。
Following the Offering, Fortius owns 36 Class A Shares and 106,043 Class B Shares, representing 50% of the outstanding Class A Shares, 0.27% of the outstanding Class B Shares, and 16.98% of the voting rights attached to all of the Company's outstanding voting securities. Prior to the Offering, Fortius owned 24 Class A Shares and 106,043 Class B Shares, which represented 50% of the outstanding Class A Shares, 0.27% of the outstanding Class B Shares, and 12.81% of the voting rights attached to all of the Company's outstanding voting securities.
發行後,Fortius擁有36股A類股票和106,043股B類股票,佔已發行A類股票的50%,佔已發行B類股票的0.27%,以及公司所有已發行有表決權證券的16.98%。發行前,Fortius擁有24股A類股票和106,043股B類股票,佔已發行A類股票的50%,佔已發行B類股票的0.27%,佔公司所有已發行有表決權證券的12.81%。
The Acquirors acquired the above-noted Class A Shares for investment purposes. In the future, the Acquirors will evaluate their respective investment in the Company from time to time and may, based on such evaluation, market conditions and other circumstances, increase or decrease its shareholdings as circumstances require through market transactions, private agreements, or otherwise.
收購方出於投資目的收購了上述A類股票。將來,收購方將不時評估各自在公司的投資,並可能根據此類評估、市場狀況和其他情況,通過市場交易、私人協議或其他方式視情況增加或減少其持股量。
The Acquirors currently have no plans or intentions which would result in a corporate transaction, a sale or transfer of a material amount of the assets of the Company or any of its subsidiaries, a change in the board of directors or management of the Company, including any plans or intentions to change the number or term of directors or to fill any existing vacancies on the board, a material change in the Company's business or corporate structure, a change in the Company's charter, bylaws or similar instruments or another action which might impede the acquisition of control of Company by any person or company, a class of securities of the Company being delisted from, or ceasing to be authorized to be quoted on, a marketplace, the Company ceasing to be a reporting issuer in any jurisdiction of Canada, a solicitation of proxies from securityholders, or an action similar to any of those enumerated.
收購人目前沒有任何計劃或意圖導致公司交易、出售或轉讓公司或其任何子公司的大量資產、公司董事會或管理層的變動,包括任何更改董事人數或任期或填補董事會現有空缺的計劃或意圖,公司業務或公司結構發生重大變化,公司章程變更,章程或類似文書或其他可能阻礙收購的行動任何人或公司對公司的控制權,公司的一類證券被從市場上除牌或停止獲准在市場上市,公司不再是加拿大任何司法管轄區的報告發行人,向證券持有人徵集代理人,或採取與所列舉的任何行爲相似的行動。
Copies of the Early Warning Reports being filed by the Acquirors may be obtained on the Company's SEDAR+ profile or by emailing rehansk@gmail.com or calling 416-786-6063 for Xorax's Early Warning Report, or by emailing anthony@firstrepubliccapital.com or calling 416-720-4360 Fortius' Early Warning.
收購方提交的預警報告的副本可在公司的SEDAR+個人資料上獲取,也可以發送電子郵件至 rehansk@gmail.com 或致電416-786-6063獲取Xorax的預警報告,或者發送電子郵件至 anthony@firstrepubliccapital.com 或致電416-720-4360 Fortius的預警報告。
Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
CSE及其監管服務提供商(該術語在CSE的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
About FSD
關於 FSD
FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD has also licensed UNBUZZD, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nu and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD continues its R&D activities to develop novel formulations for alcohol misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.
FSD是一家生物製藥公司,致力於建立創新資產和生物技術解決方案組合,用於治療具有挑戰性的神經退行性和代謝性疾病以及酒精濫用障礙,候選藥物處於不同開發階段。FSD通過其全資子公司Lucid Psycheceuticals Inc.(“Lucid”)專注於其主要化合物Lucid-MS(前身爲Lucid-21-302)(“Lucid-MS”)的研究和開發。Lucid-MS 是一種獲得專利的新化學實體,在臨床前模型中被證明可以防止和逆轉髓鞘降解,這是多發性硬化的潛在機制。FSD還向Celly Nu許可了UNBUZZD,這是一種有助於肝臟和大腦功能的天然成分、維生素和礦物質的專有配方,用於消費娛樂領域,可以快速緩解個人飲酒的影響,並有權就Celly Nu通過銷售使用許可協議授予的技術權利生產的產品所產生的收入收取特許權使用費。FSD 繼續開展研發活動,開發治療酒精濫用障礙的新配方,並繼續開發用於醫療保健領域的此類治療方法。FSD通過其全資子公司FSD Strategic Investments Inc. 維持戰略投資組合,這些貸款由住宅或商業地產擔保。
Cautionary Note Regarding Forward-Looking Statements
關於前瞻性陳述的警示說明
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the news release, such forward-looking statements include, but are not limited to, statements regarding, the Company's performance, business objectives and milestones and the anticipated timing thereof; the anticipated use of net proceeds from the Offering; the Acquirors evaluations with respect to their future investment in the Company; and the Acquirors plans with respect to future transactions or material changes.
本新聞稿中列出的某些信息可能包含前瞻性陳述,這些陳述涉及大量已知和未知的風險和不確定性,其中某些風險和不確定性超出了公司的控制範圍。前瞻性陳述通常以 “計劃”、“繼續”、“預期”、“項目”、“打算”、“相信”、“預期”、“估計”、“可能”、“將”、“可能”、“潛在”、“提議” 和其他類似詞語爲特徵,或關於某些事件或條件 “可能” 或 “將” 發生的陳述 或者被實現和其他類似的表達方式。前瞻性陳述基於陳述發表之日管理層的估計和意見。在新聞稿中,此類前瞻性陳述包括但不限於有關公司業績、業務目標和里程碑及其預期時機的陳述;本次發行淨收益的預期用途;收購方對公司未來投資的評估;以及收購方對未來交易或重大變更的計劃。
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the Company's ability to comply with all applicable regulations and laws, including environmental, health and safety laws; the Company having sufficient working capital for future operating activities; the ability of the Company to achieve its business objectives and milestones and the anticipated timing of execution; the Company's ability to continue as a going concern and the Company's ability to use the proceeds from the Offering for the business objectives outlined herein.
在本新聞稿中做出前瞻性陳述時,公司應用了幾項實質性假設,包括但不限於:公司遵守所有適用法規和法律的能力,包括環境、健康和安全法;公司有足夠的營運資金用於未來的運營活動;公司實現其業務目標和里程碑的能力以及預期的執行時間;公司繼續經營的能力以及公司使用所得收益的能力此處概述的業務目標的產品。
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: changes in general economic, business and political conditions, including changes in the financial markets; consents or authorizations required; changes in laws, regulations and policies affecting the Company's operations; currency fluctuations; environmental issues and liabilities; the potential impact of the announcement or consummation of the Offering on relationship, including with regulatory bodies, employees, suppliers, customers and competitors; the inability of the Company to obtain additional financing for continued operations on terms acceptable to the Company; the lack of control over the Company's investees; risks relating to investing in the Class A Shares and Class B Shares; risks relating to the use of proceeds from the Offering; volatility in the market price of the Class A Shares and Class B Shares; dilution of shareholders' holdings; negative operating cash flow; the negative effects of interest rate and exchange rate changes; the potential impact of health crises and market instability due to the COVID-19 pandemic; risks relating to the Company s reliance on key employees; limitations in the liquidity of the Class A Shares; litigation risks; the Company's inability to expand into new business areas and geographic markets; management of growth; and the Company's inability to continue as a going concern.
上述前瞻性陳述和假設列表並不詳盡。由於前瞻性陳述涉及未來的事件和狀況,因此就其本質而言,它們涉及固有的風險和不確定性。由於多種因素和風險,實際結果可能與此類前瞻性陳述目前的預期或暗示的結果存在重大差異。其中包括:總體經濟、商業和政治條件的變化,包括金融市場的變化;需要獲得同意或授權;影響公司運營的法律、法規和政策的變化;貨幣波動;環境問題和責任;本次發行的宣佈或完成對關係,包括與監管機構、員工、供應商、客戶和競爭對手的關係的潛在影響;公司無法按條款爲持續運營獲得額外融資公司可以接受;缺乏對公司被投資者的控制權;與投資 A 類股票和 B 類股票相關的風險;與使用本次發行收益相關的風險;A 類股票和 B 類股票的市場價格波動;股東持有的稀釋;運營現金流爲負;利率和匯率變動的負面影響;COVID-19 疫情導致的健康危機和市場不穩定的潛在影響;與公司依賴關鍵員工有關的風險;限制A類股票的流動性;訴訟風險;公司無法向新的業務領域和地域市場擴張;增長管理;以及公司無法繼續經營業務。
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
如果這些風險或不確定性中的一項或多項成爲現實,或者前瞻性陳述所依據的假設被證明不正確,則實際結果可能與本文描述的預期、計劃、預期、相信、估計或預期的結果存在重大差異。儘管公司試圖確定可能導致實際業績存在重大差異的重要風險、不確定性和因素,但可能還有其他因素導致業績與預期、估計或預期不符。除非適用法律另有要求,否則公司無意更新這些前瞻性信息,也不承擔任何義務。
Contacts:
聯繫人:
FSD Pharma Inc.
FSD Pharma Inc.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, FSD Pharma Inc.
Email: Zsaeed@fsdpharma.com
Telephone: (416) 854-8884
Zeeshan Saeed,FSD Pharma Inc. 創始人、首席執行官兼董事會執行聯席主席
電子郵件:Zsaeed@fsdpharma.com
電話:(416) 854-8884
Investor Relations
投資者關係
Email: ir@fsdpharma.com, info@fsdpharma.com
Website:
電子郵件:ir@fsdpharma.com,info@fsdpharma.com
網站:
ClearThink
ClearTh
Email: nyc@clearthink.capital
Telephone: (917) 658-7878
電子郵件:nyc@clearthink.capital
電話:(917) 658-7878
SOURCE: FSD Pharma Inc.
來源:FSD Pharma Inc.